, announces that the first cohort of healthy volunteers have successfully been dosed with AX-202 – a first-in-class anti-S100A4 monoclonal antibody (mAb). The trial is led by Professor David Singh at the Medicines Evaluation Unit in Manchester, UK.

The double-blind, placebo-controlled trial aims to establish the safety and tolerability of AX-202 and is expected to enroll a total of 40 healthy volunteers and 18 patients with mild to moderate psoriasis. Trial results are expected in 2024, aiming to support the initiation of a clinical program in patients with systemic sclerosis.

Systemic sclerosis is a rare, life-threatening disease characterized by progressive fibrosis involving the skin and internal organs. Current treatment options are limited and new disease-modifying therapies are needed to improve and extend the lives of systemic sclerosis patients.

Arxx Therapeutics initiates first-in-human trial